Effectiveness and safety of upadacitinib in a real-world cohort of patients with Crohn’s disease in the UK: a multicentre retrospective cohort study

Objective Upadacitinib is the first Janus kinase inhibitor and oral advanced therapy licensed for Crohn’s disease (CD). Following NICE approval in 2023, real-world data on outcomes are limited. The effectiveness and safety of upadacitinib in a cohort of patients with CD was assessed.Methods A multic...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Thomas Morris, Richard C G Pollok, Jimmy Limdi, Christian Selinger, Tim Raine, Anjan Dhar, Polychronis Pavlidis, Chaonan Dong, Mark Samaan, Sara McCartney, Charlie Lees, Paul Harrow, Susan Ritchie, Chirag Patel, Alexandra Kent, Emma Johnston, Christopher Andrew Lamb, Jie Han Yeo, Lucy Hicks, Kamal V Patel, Klaartje Bel Kok, Phil Harvey, Melissa Hale, Chandni Radia, Mohammed Allah-Ditta, R Alexander Speight, Puneet Chhabra, Fiona Rees, Konstantina Rosiou, Lushen Pillay, Yaa Danso, Dania Al-Zarrad, Katie Yeung, Hannah Trodden-Mittnacht, Karishma Sethi-Arora, Alex Elford, Ruth Rudling, Kimberley Butler, Sonia Kalyanji, Alice Hewitt, Jennifer Toft, Xinyi Choon, Nick N Burr
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMJ Publishing Group 2025-10-01
סדרה:	BMJ Open Gastroenterology
גישה מקוונת:	https://bmjopengastro.bmj.com/content/12/1/e001916.full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!